Cargando…

Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study

Background: Olaparib maintenance therapy has shown efficacy and tolerability in patients with platinum-sensitive, high-grade serous recurrent ovarian cancer (HSROC) with BRCA1/2 mutation (BRCAm). Our aim was to present real-world experience with olaparib in Korea. Method: We included HSROC patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paik, E Sun, Lee, Yong Jae, Lee, Jung-Yun, Shin, Wonkyo, Park, Sang-Yoon, Kim, Se Ik, Kim, Jae-Weon, Choi, Chel Hun, Kim, Byoung-Gie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912318/ https://www.ncbi.nlm.nih.gov/pubmed/31717415 http://dx.doi.org/10.3390/jcm8111920

Ejemplares similares

Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer
por: Paik, E Sun, et al.
Publicado: (2021)

Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4
por: Kim, Yoo-Na, et al.
Publicado: (2023)

A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)
por: Lee, Yong Jae, et al.
Publicado: (2021)

Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer
por: Kim, Se Ik, et al.
Publicado: (2019)

Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer
por: Paik, E Sun, et al.
Publicado: (2018)

Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting
por: Dougherty, Brian A., et al.
Publicado: (2017)

A comparison of uterine papillary serous, clear cell carcinomas, and grade 3 endometrioid corpus cancers using 2009 FIGO staging system
por: Kim, Ha-Jeong, et al.
Publicado: (2013)

Which is worse: uterine papillary serous carcinomas or carcinosarcomas?
por: Song, Taejong, et al.
Publicado: (2011)

Prognostic factors for recurrence and survival in uterine leiomyosarcoma: Korean single center experience with 50 cases
por: Paik, E Sun, et al.
Publicado: (2019)

Proteomic Discovery of Biomarkers to Predict Prognosis of High-Grade Serous Ovarian Carcinoma
por: Kim, Se Ik, et al.
Publicado: (2020)

Impact of hemodynamic instability during cytoreductive surgery on survival in high-grade serous ovarian carcinoma
por: Kim, Se Ik, et al.
Publicado: (2022)

Optimal cutoff age for predicting prognosis associated with serous epithelial ovarian cancer: what is the best age cutoff?
por: Kim, Jihye, et al.
Publicado: (2018)

A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D
por: Lee, Jung-Yun, et al.
Publicado: (2019)

Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes
por: Sohn, Min-Hwan, et al.
Publicado: (2021)

Clinical characteristics and outcomes of placental site trophoblastic tumor: experience of single institution in Korea
por: Lee, Hye-joo, et al.
Publicado: (2018)

Prognostic Relevance of BRCA1 Expression in Survival of Patients With Cervical Cancer
por: Paik, E Sun, et al.
Publicado: (2021)

Comparisons of survival outcomes between bevacizumab and olaparib in BRCA-mutated, platinum-sensitive relapsed ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3052)
por: Kim, Se Ik, et al.
Publicado: (2021)

Proteomic Discovery of Plasma Protein Biomarkers and Development of Models Predicting Prognosis of High-Grade Serous Ovarian Carcinoma
por: Kim, Se Ik, et al.
Publicado: (2023)

Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer
por: Shin, Wonkyo, et al.
Publicado: (2018)

A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial
por: Park, Junsik, et al.
Publicado: (2021)

Prevalence and oncologic outcomes of BRCA1/2 mutation and variant of unknown significance in epithelial ovarian carcinoma patients in Korea
por: Seo, Jun Hyeong, et al.
Publicado: (2019)

Olaparib and somatic BRCA mutations
por: George, Angela, et al.
Publicado: (2017)

Controversies in the management of endometrial cancer: a survey of the Korean Gynecologic Oncology Group
por: Lee, Jung-Yun, et al.
Publicado: (2015)

Olaparib Monotherapy for BRIP1-Mutated High-Grade Serous Endometrial Cancer
por: Nakamura, Kohei, et al.
Publicado: (2020)

Metastatic Skin Lesions on Lower Extremities in a Patient with Recurrent Serous Papillary Ovarian Carcinoma: A Case Report and Literature Review
por: Kim, Moon-Kyung, et al.
Publicado: (2012)

Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial
por: Colombo, Nicoletta, et al.
Publicado: (2021)

Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial
por: Lee, Jung-Yun, et al.
Publicado: (2022)

Effect of BRCA1/2 Mutational Status on Survival Outcomes According to Secondary Cytoreductive Surgery and Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer: A Real-World Evidence Study
por: Kim, Se Ik, et al.
Publicado: (2023)

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer
por: Ledermann, Jonathan A, et al.
Publicado: (2016)

Clinical outcomes of patients with clear cell and endometrioid ovarian cancer arising from endometriosis
por: Paik, E Sun, et al.
Publicado: (2018)

Survival Effects of Cytoreductive Surgery for Refractory Patients after Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer
por: Shin, Wonkyo, et al.
Publicado: (2020)

Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer
por: Eoh, Kyung Jin, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer
por: Li, Na, et al.
Publicado: (2021)

Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D
por: Park, Junsik, et al.
Publicado: (2023)

Expression of fibroblast growth factor receptor family members is associated with prognosis in early stage cervical cancer patients
por: Choi, Chel Hun, et al.
Publicado: (2016)

Analysis of adverse events and quality of life in high-grade serous ovarian cancer patients with Olaparib maintenance therapy: A single-center study in China
por: Jiang, Yi, et al.
Publicado: (2023)

Feasibility of laparoscopic cytoreduction in patients with localized recurrent epithelial ovarian cancer
por: Paik, E Sun, et al.
Publicado: (2016)

Comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer
por: Paik, E Sun, et al.
Publicado: (2016)

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
por: DiSilvestro, Paul, et al.
Publicado: (2023)

The Asia-Pacific Gynecologic Oncology Trials Group (APGOT): building a Pan-Asian and Oceania women’s cancer research organization
por: Tan, David, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_233dagnjn4gj3rkdg37qfaqo2l